January 29, 2018
Forest Laboratories Inc. prevailed on Monday against claims by a health and benefit fund and a pair of mothers that it fraudulently promoted Celexa and Lexapro for pediatric depression, putting long-running Massachusetts multidistrict litigation against the company to rest.
January 03, 2018
A Massachusetts federal judge on Tuesday ruled Forest Laboratories can't be forced to produce documents from a congressional probe into the use of antidepressants in children, rejecting objections from parents accusing the company of fraudulently promoting Celexa and Lexapro for pediatric depression.
October 16, 2017
Parents who bought antidepressants for their children urged a Massachusetts federal court on Friday to keep alive multidistrict litigation alleging Forest Laboratories LLC fraudulently promoted Celexa and Lexapro to treat pediatric depression, saying the FDA's finding that one treatment study was promising doesn't rule out other, contradictory evidence.
September 18, 2017
Forest Laboratories LLC urged a Massachusetts federal court Friday to dismiss claims in multidistrict litigation alleging the company fraudulently promoted antidepressants Celexa and Lexapro to treat pediatric depression, saying the parties haven't established injury or causation under the Racketeer Influenced and Corrupt Organizations Act.
August 15, 2017
A Massachusetts federal judge declined to certify a class of consumers in multidistrict litigation accusing Forest Laboratories of fraudulently promoting Celexa and Lexapro as treatments for pediatric depression, citing individual analyses that would be required to determine issues around the drugs' use and promotion.
February 28, 2017
A health care fund asked a Massachusetts federal judge on Tuesday to certify a class of health benefit providers in multidistrict litigation accusing Forest Laboratories of misleading consumers about whether Celexa and Lexapro could treat pediatric depression, saying evidence that efficacy studies were compromised backed its classwide Racketeer Influenced and Corrupt Organizations Act claim.
June 09, 2016
A Massachusetts federal judge on Thursday refused to dismiss a potential class action accusing Forest Laboratories Inc. in multidistrict litigation of misleading consumers about the efficacy of its drugs Celexa and Lexapro in treating pediatric depression, finding a mother properly alleged plausible Racketeer Influenced and Corrupt Organizations Act claims.
June 02, 2016
A Massachusetts federal judge on Thursday concluded that individual questions of causation and injury outweigh certification of a proposed class of third-party payors accusing Forest Laboratories Inc. in multidistrict litigation of misleading consumers about the efficacy of its drugs Celexa and Lexapro in treating pediatric depression.
May 09, 2016
Health care fund providers seeking to recover money lost because of Forest Laboratories' allegedly fraudulent promotion of its drugs in treating pediatric depression pressed a Massachusetts federal judge to certify their portion of the multidistrict litigation as a class, saying previous court rulings and common issues called for it.
February 29, 2016
Forest Laboratories on Friday struck back in multidistrict litigation alleging it misled consumers about the efficacy of its drugs Celexa and Lexapro in treating pediatric depression, telling a Massachusetts federal court the class claims of a pair of consumers are too individualized to be decided classwide.